ABSTRACT
Background: Diabetic macular edema is one of the most significant causes of blindness and severe visual impairment in patients with diabetes, which can result in reduced quality of life. Three commonly used intravitreous VEGF inhibitors aflibercept, bevacizumab and ranibizumab have been shown to be beneficial and relatively safe for the treatment of diabetic macular edema, but only aflibercept and ranibizumab are approved by the Food and Drug Administration [FDA] for this indication
Aim of the Work: To compare between the effect of ranibizumab and aflibercept in patients with diabetic macular edema as a diabetic retinopathy complication that leads to visual impairment
Patients and Methods: A prospective study of 20 patients [20 eyes] was conducted in Al-Mouneer diabetic eye center with three times injection one month apart. The patients were divided into two groups, Group A was consisted of 10 patients who received ranibizumab as 0.5 mg [0.05ml of 10mg/ml solution] an intra vitreal injection. Group B was consisted of 10 patients who received aflibercept 2 mg [0.05mL of 40mg/ml solution] as an intra vitreal injection with follow up for three months
Results: A statistically significant difference over the time through BCVA and central macular thickness with ranibizumab. There was also a statistically significant difference over the time through BCVA, central macular thickness and IOP with aflibercept
Conclusion: There was more improvement in BCVA which was significant and more reduction in central macular thickness with ranibizumab than with aflibercept
Recommendations: Larger group studies to confirm our results; longer term study for the effect of ranibizumab and aflibercept injection on the central macular thickness and IOP and comparing the effect of single injection versus multiple injections. Searching for the causes of resistance or delayed response to the intravitreal injections in some patients
ABSTRACT
Background: age-related Macular Degeneration [AMD] is a progressive, degenerative disease that affects the macula and it isone of the most common leading causes of irreversible vision loss in old patients with age more thanfifty. Optical coherence tomography angiography [OCTA] can detect the presence of choroidal neovascularization [CNV], structural changes in AMD; moreover, changes in choroidal blood vessel flow
Aim: to assess and compare structural retinal changes in patients with neovascular age-related macular degeneration [AMD] treated with 2mg/0.1ml intravitreal aflibercept three times with an interval of one month each
Patients and methods: twenty eyes of non-diabetic non-hypertensive ARMD patients were included. They received 2mg/0.1ml intravitreal aflibercept three times with an interval of one month each. OCTA was done before the first injection and was repeated one month after the third injection
Results: the area size and the GLD of the CNV had highly statistically significantly improved after 2mg/0.1ml three intravitreal aflibercept injections
Conclusion: aflibercept is an effective treatment in AMD; it can decrease the area size, GLD and thickness of the CNV. OCTA is an effective tool that can provide a noninvasive method in the diagnosis and follow up of the activity and anatomical changes in AMD